Last reviewed · How we verify
AMT-676
AMT-676 is a small-molecule allosteric modulator of the calcium-sensing receptor (CaSR) that enhances receptor sensitivity to extracellular calcium.
AMT-676 is a small-molecule allosteric modulator of the calcium-sensing receptor (CaSR) that enhances receptor sensitivity to extracellular calcium. Used for Secondary hyperparathyroidism in patients with chronic kidney disease.
At a glance
| Generic name | AMT-676 |
|---|---|
| Sponsor | Multitude Therapeutics Inc. |
| Drug class | Calcimimetic agent |
| Target | Calcium-sensing receptor (CaSR) |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Endocrinology |
| Phase | Phase 2 |
Mechanism of action
By allosterically modulating the calcium-sensing receptor, AMT-676 increases the receptor's responsiveness to circulating calcium levels, thereby promoting parathyroid hormone (PTH) suppression and reducing serum calcium. This mechanism is intended to treat secondary hyperparathyroidism in patients with chronic kidney disease by restoring more physiologic calcium homeostasis without requiring exogenous calcium supplementation.
Approved indications
- Secondary hyperparathyroidism in patients with chronic kidney disease
Common side effects
- Hypocalcemia
- Nausea
- Vomiting
Key clinical trials
- A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer (PHASE2)
- AMT-676 in Patients With Advanced Solid Tumors (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMT-676 CI brief — competitive landscape report
- AMT-676 updates RSS · CI watch RSS
- Multitude Therapeutics Inc. portfolio CI